Cargando…
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
BACKGROUND: The rate of development of new orphan drugs continues to grow. As a result, reimbursing orphan drugs on an exceptional basis is increasingly difficult to sustain from a health system perspective. An understanding of the value that societies attach to providing orphan drugs at the expense...
Autores principales: | Paulden, Mike, Stafinski, Tania, Menon, Devidas, McCabe, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342524/ https://www.ncbi.nlm.nih.gov/pubmed/25412735 http://dx.doi.org/10.1007/s40273-014-0235-x |
Ejemplares similares
-
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011) -
Moving beyond the Court of Public Opinion: A Citizens’ Jury Exploring the Public’s Values around Funding Decisions for Ultra-Orphan Drugs
por: Stafinski, Tania, et al.
Publicado: (2022) -
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
por: Menon, Devidas, et al.
Publicado: (2015) -
Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review
por: Young, Andrea, et al.
Publicado: (2017) -
HTA decision-making for drugs for rare diseases: comparison of processes across countries
por: Stafinski, Tania, et al.
Publicado: (2022)